Drug Trial Radar · NCT06280209
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
18
Actual
Start
Jan 3, 2024
Primary completion
Apr 14, 2027
Study completion Apr 14, 2027
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Feb 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 4 years, up to 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the safety and tolerability of BMN 351 in participants with Duchenne Muscular Dystrophy (DMD) with a genetic mutation amenable to exon 51 skipping.
Conditions
- Duchenne Muscular Dystrophy
Interventions
BMN 351Drug
Anti-sense Oligonucleotide BMN 351 will be administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate and safety and tolerability of single and multiple doses of BMN 351 (incidence, severity, and dose-relationship of adverse effects and changes in laboratory parameters).Time frame: Up to 97 weeks.
Locations
7 sites in 5 countries. Site status is shown where the registry gives one.
Fondazione Serena ETS - Centro Clinico NeMO Milano
Milan, Italy
UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Rome, Italy
Leids Universitair Medisch Centrum
Leiden, Netherlands
Hospital Sant Joan de Deu
Barcelona, Spain
Hospital Viamed Santa Angela De la Cruz
Seville, Spain
Yeditepe University Kosuyolu Hospital
Istanbul, Turkey (Türkiye)
Great Ormond Street Hospital NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.